CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Menevit anti-oxidantdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00100269
NCT00100269Phase 3Completed
CompareCT.gov

A Randomized Control Trial of the Menevit Anti-Oxidant Therapy for the Treatment of Male Infertility

Repromed·interventional·Posted Dec 28, 2004·Updated May 3, 2006

In Brief

A Phase 3 clinical trial evaluating Menevit anti-oxidant for Infertility, Male and Oxidative Stress. Completed, across 1 site.

Detailed Summary

Oxidative stress related damage to sperm is believed to be a major cause of male infertility. The object of the Menevit study is to investigate the role of a novel anti-oxidant preparation (Menevit) on sperm function, embryo quality and pregnancy rates in an in vitro fertilization (IVF) setting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfertility, Male, Oxidative Stress
CountriesAustralia
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 28, 2004
Enrollment StartDec 1, 2004
Study CompletionMar 1, 2006
TodayJul 2, 2026
Posted 21.5 years ago

Interventions

Menevit anti-oxidantdrug